ClinicalTrials.gg
CompletedNCT02082210Updated Dec 19, 2020Results posted

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

A Phase 1/2 interventional study of Emibetuzumab and Ramucirumab in Advanced Cancer, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
97
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 566 studies in Liver Neoplasms with a site in United States — 82 open to participants now, 122 under way, 6 of them phase 3. Liver Neoplasms · United States.

Enrollment
95th of 433
97 · median 30
Started
2014
with 19 others
Phase 1/2
51 of 566
6 open now
Registered
294th of 566
by date

Among the 566 studies in Liver Neoplasms with a site in United States, this one is the 95th largest by enrollment of the 433 interventional ones that give a count, is one of 20 that started in 2014, is one of 51 in phase 1/2, and was the 294th registered.

Liver Neoplasms

1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

82 of the 566 studies in Liver Neoplasms with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 566 studies in Liver Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of Emibetuzumab will be given in combination with a fixed dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule and dose range of Emibetuzumab and ramucirumab has been established, Part B of the study will confirm safety and to see how well certain tumors respond to the combination of study drugs. The average amount of time on study is expected to be about 6 months.

03

Conditions studied

  • Advanced Cancer
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Hepatocellular Cancer
  • Renal Cell Carcinoma
  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have histological or cytological confirmed diagnosis of the following tumor types that is advanced and/or cancer and must be, in the judgment of the investigator, an appropriate participant for experimental therapy

    • Part A: Any type of solid tumor ("all comer")
    • Part B1: Gastric or Gastroesophageal Junction (GEJ) adenocarcinoma
    • Part B2: Hepatocellular cancer (excluding fibrolamellar carcinoma)
    • Part B3: Renal cell carcinoma (any histology)
    • Part B4: Non-small cell lung cancer (squamous or non-squamous)
  • Have at least 1 outside of the central nervous system (CNS) whose presence is assessable using standard techniques by (RECIST) version 1.1.
  • Availability of a tumor sample taken after progression on the most recent line of systemic tumor therapy or willing to undergo a tumor pre-study treatment.
  • Have a performance status of ≤ 2 on the (ECOG) scale in Part A and ≤ 1 on the ECOG scale in Part B.
  • Have adequate organ function.
  • Routine urinalysis showing ≤1+ protein or protein/creatinine ratio \<0.5. For proteinuria ≥2+ or urine protein/creatinine ratio ≥0.5, 24-hour urine must be collected and the level must be \<1 gram of protein in 24 hours for subject enrollment.
  • Have discontinued all previous cancer therapies and any agents that have not received regulatory approval for any indication, for at least 21 days or 5 halflives prior to study enrollment, whichever is shorter, and recovered from the acute effects for therapy.
  • Have an estimated , in the judgment of the investigator, that will permit the participant to complete 8 weeks (2 cycles) of treatment.
  • Males and females with : Must agree to use medically approved precautions during the study and for at least 3 months following the last dose of study drug. Females with must have had a negative serum pregnancy test 7 days before the first dose of study drug and must not be breast-feeding.

Exclusion criteria

Exclusion Criteria:

  • Have serious pre-existing medical conditions (at the discretion of the investigator, such as severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation).
  • Have a history of hypertensive crisis or hypertensive encephalopathy or current poorly controlled hypertension despite standard medical management.
  • Participant has experienced any arterial thromboembolic event (ATE), including myocardial infarction, unstable angina pectoris, cerebrovascular accident, or , within 6 months prior to receiving study drugs.
  • Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the 3 months prior to receiving study drugs.
  • Are receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents. Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that they are on low-molecular weight heparin or oral factor Xa inhibitors.
  • The participant is receiving chronic therapy with nonsteroidal anti-inflammatory drugs or other antiplatelet agents. Aspirin use at doses up to 325 mg/day is permitted.
  • Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to receiving study drugs.
  • Have a history of GI perforation and/or fistulae within 6 months prior to receiving study drugs.
  • Have congestive heart failure (CHF) class ≥3 or symptomatic or poorly controlled cardiac arrhythmia.
  • Have undergone major surgery within 28 days prior to receiving study drugs.
  • Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to receiving study drugs.
  • Have a known active fungal, bacterial, and/or known viral infection. Hepatocellular cancer participants with chronic viral (B or C) hepatitis are eligible if they retain adequate liver function.
  • Have liver cirrhosis with a Stage of B or C.
  • Have symptomatic CNS (with the exception of medulloblastoma) or .
  • Have (QTc) interval of >470 milliseconds on screening (ECG).
  • Have received previous treatment with ramucirumab or Emibetuzumab, except for participants enrolled in cohort B1 (Gastric or GEJ adenocarcinoma) and B4 (non- small cell lung cancer) who may have received previous ramucirumab treatment.
  • Known to any of the treatment components of ramucirumab or Emibetuzumab.
  • Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.
  • Are pregnant or breastfeeding.
  • For Part B4 (non-small cell lung cancer) only:

    • The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer
    • Participants with a history of gross hemoptysis within 2 months prior to study treatment
    • The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Emibetuzumab + Ramucirumab (Part A)

    Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.

    Drug: Emibetuzumab · Drug: Ramucirumab

  • Experimental
    Emibetuzumab + Ramucirumab (Part B)

    Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.

    Drug: Emibetuzumab · Drug: Ramucirumab

Interventions

  • Administered Intravenously (IV)

    Also known as: LY2875358

  • Administered Intravenously (IV)

    Also known as: LY3009806, IMC-1121B

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

    DLT is defined as an adverse event during Cycle1 that is possibly, probably, or definitely related to treatment with Emibetuzumab in combination with fixed regimen of Ramucirumab \& fulfills any 1 of the following criterion using NCI CTCAE Version 4.03: Grade 3 non-hematological toxicity. Exceptions will be made for:Nausea, vomiting, diarrhea, constipation, or skin rash that persists for ≤3 days following appropriate supportive care intervention. Grade 3 hypertension in which systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg persist \<7 days after intensified antihypertensive therapy is initiated. Grade 4 hematological toxicity of ≥7 days duration. ≥Grade 3 thrombocytopenia with ≥Grade 2 bleeding. Any febrile neutropenia. Any other significant toxicity deemed by the primary investigator \& Lilly clinical research personnel to be dose-limiting (eg, any toxicity that is possibly related to the study medication that requires the withdrawal of participant from study Cycle1).

    Time frame: Baseline through Cycle 1 (28 day cycle)

  2. Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]

    ORR is the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Baseline through Measured Progressive Disease or Death (Up to 17 months)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab

    Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab.

    Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose

  2. Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR])

    DCR is the proportion of participants who exhibit a SD or confirmed CR or PR relative to baseline. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Baseline through Measured Progressive Disease (Up to 17 months)

  3. Part B: Progression Free Survival (PFS)

    PFS was defined as the time from the date of first dose of study drug until first observation of objective (radiographically documented) PD as defined by RECIST v1.1 or death from any cause, whichever comes first. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

    Time frame: Baseline to Measured Progressive Disease or Death (Up to 17 Months)

  4. Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab

    Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) from time zero to tlast of Emibetuzumab.

    Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose

  5. Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab

    Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab.

    Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose

  6. Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies

    Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:4 for anti-emibetuzumab antibodies).

    Time frame: Baseline through 46 Months

  7. Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab

    Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab.

    Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose

  8. Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies

    Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:10 for anti-ramucirumab antibodies).

    Time frame: Baseline through 46 Months

07

Results

Posted Dec 19, 2020

Participant flow

Part A: Completers are those who have completed one cycle of treatment. Part B: Completers are those who 1)Have measurable disease at baseline and at least one post-baseline tumor assessment; and 2) Were treated until PD or death, or discontinued due to an AE and completed the required follow-up.

Participant flow — Overall Study
MilestonePart A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
Started3316451515
Received at least one dose of study drug3316451515
Completed3313391213
Not completed003632
Withdrew: Death001110
Withdrew: Withdrawal by subject000122
Withdrew: Clinical progression000100
Withdrew: No post-baseline tumor assesment001200
Withdrew: Physician decision001100

Outcome measures

PrimaryNumber of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

DLT is defined as an adverse event during Cycle1 that is possibly, probably, or definitely related to treatment with Emibetuzumab in combination with fixed regimen of Ramucirumab \& fulfills any 1 of the following criterion using NCI CTCAE Version 4.03: Grade 3 non-hematological toxicity. Exceptions will be made for:Nausea, vomiting, diarrhea, constipation, or skin rash that persists for ≤3 days following appropriate supportive care intervention. Grade 3 hypertension in which systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg persist \<7 days after intensified antihypertensive therapy is initiated. Grade 4 hematological toxicity of ≥7 days duration. ≥Grade 3 thrombocytopenia with ≥Grade 2 bleeding. Any febrile neutropenia. Any other significant toxicity deemed by the primary investigator \& Lilly clinical research personnel to be dose-limiting (eg, any toxicity that is possibly related to the study medication that requires the withdrawal of participant from study Cycle1).

Time frame:
Baseline through Cycle 1 (28 day cycle)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
ParticipantsPart A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)000000
PrimaryPart B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]

ORR is the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Baseline through Measured Progressive Disease or Death (Up to 17 months)
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
percentage of participantsPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]6.3 (0 to 30)6.7 (0 to 20)0 (0 to 20)6.7 (0 to 30)
SecondaryPharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab

Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab.

Time frame:
Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose
Reported as:
Geometric mean · Microgram per milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab
Microgram per milliliter (µg/mL)All Parts - 750 mg EmibetuzumabAll Parts - 2000 mg Emibetuzumab
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab210 ± 27575 ± 33
SecondaryPart B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR])

DCR is the proportion of participants who exhibit a SD or confirmed CR or PR relative to baseline. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Baseline through Measured Progressive Disease (Up to 17 months)
Reported as:
Number · percentage of participants
Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR])
percentage of participantsPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR])50 (20 to 80)60 (40 to 70)46.7 (20 to 70)86.7 (60 to 100)
SecondaryPart B: Progression Free Survival (PFS)

PFS was defined as the time from the date of first dose of study drug until first observation of objective (radiographically documented) PD as defined by RECIST v1.1 or death from any cause, whichever comes first. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.

Time frame:
Baseline to Measured Progressive Disease or Death (Up to 17 Months)
Reported as:
Median · months
Part B: Progression Free Survival (PFS)
monthsPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
Part B: Progression Free Survival (PFS)1.64 (1.35 to 4.60)5.42 (1.64 to 8.12)2.92 (1.18 to 7.39)6.57 (2.86 to 9.66)
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab

Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) from time zero to tlast of Emibetuzumab.

Time frame:
Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose
Reported as:
Geometric mean · Microgram * hour per milliliter(µg*h/mL)
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab
Microgram * hour per milliliter(µg*h/mL)All Parts - 750 mg EmibetuzumabAll Parts - 2000 mg Emibetuzumab
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab29800 ± 2686500 ± 25
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab

Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab.

Time frame:
Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies

Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:4 for anti-emibetuzumab antibodies).

Time frame:
Baseline through 46 Months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies
ParticipantsPart A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies000300
SecondaryPharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab

Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab.

Time frame:
Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Emergent Anti-Ramucirumab Antibodies

Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:10 for anti-ramucirumab antibodies).

Time frame:
Baseline through 46 Months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies
ParticipantsPart A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies100410

Adverse events

Collected over Up to 46 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - 750 mg Emibetuzumab0/3 (0%)2/3 (66.7%)3/3 (100%)
Part A - 2000 mg Emibetuzumab0/3 (0%)2/3 (66.7%)3/3 (100%)
Part B - Gastric3/16 (18.8%)4/16 (25%)15/16 (93.8%)
Part B - HCC4/45 (8.9%)19/45 (42.2%)45/45 (100%)
Part B - RCC1/15 (6.7%)5/15 (33.3%)15/15 (100%)
Part B - NSCLC1/15 (6.7%)3/15 (20%)14/15 (93.3%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventPart A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
NauseaGastrointestinal disorders1/30/30/160/450/150/15
OesophagitisGastrointestinal disorders1/30/30/160/450/150/15
VomitingGastrointestinal disorders1/30/30/160/450/150/15
PainGeneral disorders1/30/30/160/450/150/15
PyrexiaGeneral disorders0/31/30/162/450/150/15
PneumoniaInfections and infestations1/30/32/160/450/150/15
Back painMusculoskeletal and connective tissue disorders0/31/30/160/450/150/15
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/31/30/160/451/151/15
Pericardial effusionCardiac disorders0/30/30/160/451/151/15
Abdominal distensionGastrointestinal disorders0/30/30/160/451/150/15
Most frequent other events
Showing 10 of 170
Most frequent other events
EventPart A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLC
Oedema peripheralGeneral disorders3/30/36/1626/455/155/15
FatigueGeneral disorders1/31/311/1625/456/159/15
Decreased appetiteMetabolism and nutrition disorders2/30/38/1611/453/153/15
DyspnoeaRespiratory, thoracic and mediastinal disorders1/31/32/1612/458/152/15
NauseaGastrointestinal disorders1/30/38/1612/454/154/15
VomitingGastrointestinal disorders1/30/36/167/451/155/15
ThrombocytopeniaBlood and lymphatic system disorders1/30/30/167/451/150/15
ConstipationGastrointestinal disorders0/30/35/1612/453/155/15
Gingival bleedingGastrointestinal disorders1/30/30/161/451/151/15
Gingival swellingGastrointestinal disorders1/30/30/160/450/150/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLCTotal
Mean41.3 ± 20.662.0 ± 13.562.6 ± 9.163.4 ± 9.563.1 ± 10.159.9 ± 8.662.0 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Part A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLCTotal
Female304113627
Male03123412970
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLCTotal
Hispanic or Latino0013206
Not Hispanic or Latino331536131484
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLCTotal
American Indian or Alaska Native0001001
Asian0007029
Native Hawaiian or Other Pacific Islander0000000
Black or African American0113016
White321432141176
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)Part A - 750 mg EmibetuzumabPart A - 2000 mg EmibetuzumabPart B - GastricPart B - HCCPart B - RCCPart B - NSCLCTotal
United States331645151597
08

Study locations

4 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114-3117, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Dec 2017, 44 months.

Results were first posted in Dec 2020, 3 years after primary completion. A results delay was requested in Nov 2018.

Of 33 phase 1/2 interventional studies under Liver Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 72. This study's 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2014
First posted
Mar 10, 2014
StartActual
Mar 7, 2014
Primary completionActual
Dec 5, 2017
CompletionActual
Jan 24, 2018
Results delay requested
Nov 30, 2018
Results first posted
Dec 19, 2020
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02082210
Responsible party
Sponsor
First posted
Mar 10, 2014
Start date
Mar 7, 2014
Primary completion
Dec 5, 2017
Completion
Jan 24, 2018
Results posted
Dec 19, 2020
Last update
Dec 19, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Emibetuzumab · Ramucirumab

Start the discussion